Cranioectodermal dysplasia

Cranioectodermal dysplasia (CED), also known as Sensenbrenner syndrome or Levin syndrome, is a rare autosomal recessive ciliopathy characterized by skeletal, ectodermal, and multi-organ abnormalities. The condition is caused by mutations in genes involved in intraflagellar transport (IFT122, WDR35/IFT121, IFT43, and WDR19/IFT144), which are essential for the proper function of primary cilia — cellular structures critical for signaling during development. Key clinical features include craniofacial abnormalities such as dolichocephaly (elongated skull), sagittal craniosynostosis, frontal bossing, and a characteristic facial appearance with full cheeks, a small nose, and widely spaced teeth. Ectodermal findings include sparse, fine hair, small or abnormally shaped teeth (hypodontia, microdontia), and short, dystrophic nails. Skeletal manifestations include short limbs, brachydactyly (short fingers), narrow thorax, and short ribs. Growth retardation leading to short stature is common. Beyond the skeletal and ectodermal systems, cranioectodermal dysplasia can affect the kidneys (nephronophthisis-like tubulointerstitial nephropathy, which may progress to renal failure), the liver (hepatic fibrosis), and the eyes (retinal dystrophy). Renal and hepatic complications are the primary determinants of long-term prognosis and can be life-threatening. There is no specific cure for CED; treatment is supportive and multidisciplinary, including surgical management of craniosynostosis, dental care, monitoring and management of renal and hepatic function, and orthopedic interventions as needed. Early detection of organ involvement, particularly kidney disease, is critical for optimizing outcomes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Cranioectodermal dysplasia